Matthew L. Ulrickson
A5013730166- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Biosimilars and Bioanalytical Methods
- Cutaneous lymphoproliferative disorders research
- Immune Cell Function and Interaction
- Health Systems, Economic Evaluations, Quality of Life
- Chronic Lymphocytic Leukemia Research
- Fungal Infections and Studies
- Integrated Circuits and Semiconductor Failure Analysis
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer Immunotherapy and Biomarkers
- Biomedical Ethics and Regulation
- Acute Myeloid Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Polyomavirus and related diseases
- Viral-associated cancers and disorders
- Childhood Cancer Survivors' Quality of Life
- Statistical Methods in Clinical Trials
- HER2/EGFR in Cancer Research
- Eosinophilic Disorders and Syndromes
- T-cell and Retrovirus Studies
- Mast cells and histamine
- Neutropenia and Cancer Infections
Banner MD Anderson Cancer Center
2016-2025
The University of Texas MD Anderson Cancer Center
2016-2025
Banner Health
2023
Banner Gateway Medical Center
2023
Seattle Cancer Care Alliance
2020
Case Western Reserve University
2020
Medical College of Wisconsin
2020
University of Maryland, Baltimore
2020
Cleveland Clinic
2020
Cornell University
2020
In an analysis of the primary outcome this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), autologous anti-CD19 chimeric antigen receptor T-cell therapy, as second-line treatment had significantly longer event-free survival than those standard care. Data were needed on longer-term outcomes. Download a PDF Research Summary. we randomly assigned in 1:1 ratio to receive either axi-cel care (two three cycles...
High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study (ClinicalTrials.gov NCT03761056) we evaluated axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, as part of treatment in 40 patients high-risk LBCL. This trial completed accrual. The primary outcome was complete response rate (CRR). Secondary were objective (ORR), duration (DOR),...
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Approval was supported by the phase 2, multicenter, single-arm ZUMA-5 study of axi-cel patients with R/R indolent non-Hodgkin (iNHL; N = 104), including FL and marginal zone (MZL). In primary analysis (median follow-up, 17.5 months), overall response rate (ORR) 92% (complete rate, 74%). Here, we report long-term outcomes...
Here, we report the first comparative analysis of patient-reported outcomes (PROs) with chimeric antigen receptor T-cell therapy vs standard-of-care (SOC) in second-line relapsed/refractory large B-cell lymphoma (R/R LBCL) from pivotal randomized phase 3 ZUMA-7 study axicabtagene ciloleucel (axi-cel) SOC. PRO instruments were administered at baseline, day 50, 100, 150, month 9, and every months randomization until 24 or an event-free survival event. The quality life (QoL) set comprised...
Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis ≥65 years in ZUMA-7.
Axicabtagene ciloleucel (axi-cel) is an autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that approved for the treatment of relapsed or refractory large B-cell lymphoma. Little known about long-term survivorship after CAR therapy.
Abstract In patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We compared the efficacy of auto-HCT vs. a CR. A retrospective observational study comparing (2015–2021) (2018–2021) using Center for International Blood & Marrow Transplant Research registry. Median follow-up was 49.7 months 24.7 cohort. Patients ages 18 75...
766 Background: BASECAMP-1 (NCT04981119) is a pre-screening study to identify patients with tumor-associated human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH) for interventional studies, such as EVEREST-2 (NCT06051695), phase 1/2 logic-gated chimeric receptor T-cell (CAR T) therapy MSLN-expressing cancers. MSLN cell surface protein expressed in several cancer types, including mesothelioma (MESO), colorectal (CRC), non-small lung (NSCLC), ovarian (OVCA), and pancreatic (PANC)...
ZUMA-12 is a multicenter phase 2 study that evaluated axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, as part of first-line treatment in patients with high-risk large B-cell lymphoma (LBCL). In the primary efficacy analysis (n=37; 15.9 months median follow-up), axi-cel demonstrated high rate complete responses (CR; 78%) and safety profile consistent prior experience. Here, we assessed updated outcomes from 40 treated after ≥3 years...
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and considered incurable conventional chemotherapy. Small observational studies reported allogeneic hematopoietic transplantation (allo-HCT) offers durable remissions in patients BPDCN. We report an analysis of BPDCN who received allo-HCT, using data to the Center for International Blood Marrow Transplant Research (CIBMTR). identified 164 from 78 centers underwent allo-HCT between 2007...
High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been established as a standard form of therapy for patients non-Hodgkin lymphoma (NHL). While many high-dose combinations are used, no single regimen proved superior over another. Here, we report our center's experience in NHL undergoing ASCT the combination busulfan and cyclophosphamide (Bu/Cy). This study is retrospective analysis 78 consecutive who underwent Bu/Cy at Massachusetts General Hospital Cancer Center....